Cargando…

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will re...

Descripción completa

Detalles Bibliográficos
Autor principal: Weitz, Ilene Ceil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066888/
https://www.ncbi.nlm.nih.gov/pubmed/37016661
http://dx.doi.org/10.2147/JBM.S362220